Caliso, Bernadette P.
HRN: 22-08-60 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/19/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/19/2022
10/26/2022
IV
500mg
Q8H
Obstructive Jaundice; Cholecystitis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes